Harmony Biosciences Reports Q2 2026 Results, Posts Investor Presentation

What Happened
Harmony Biosciences Holdings, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release dated August 4, 2026 and furnished that release on Form 8‑K (Exhibit 99.1). On the same date the company posted an investor presentation to its investor relations website (ir.harmonybiosciences.com) and furnished that presentation as Exhibit 99.2 to the 8‑K.

Key Details

• Filing date: August 4, 2026; quarter covered: ended June 30, 2026.
• Press release attached as Exhibit 99.1 and investor presentation attached as Exhibit 99.2 (both furnished, not “filed,” per the 8‑K).
• Company may use the investor presentation, in whole or in part, in meetings with investors and analysts.
• The investor presentation contains forward‑looking statements and includes the standard caution that actual results may differ; the 8‑K was signed by Stephen Mollichella, Senior VP, Controller and Interim Principal Financial Officer.

Why It Matters
Investors should review the press release and investor presentation for the company’s reported quarterly results, revenue/earnings details, and management commentary to assess recent performance and trends. Note that the materials are furnished (limiting certain SEC liabilities) and include forward‑looking statements subject to risks described in Harmony’s SEC filings, so projections and plans may change.